Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-FAPI-FUSCC
- Development stage
- Phase 1
- Lead developer
- Fudan University Shanghai Cancer Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**177Lu-FAPI-FUSCC** is a radiopharmaceutical designed for targeted therapy of advanced malignant solid tumors expressing fibroblast activation protein (FAP). It consists of a fibroblast activation protein inhibitor (FAPI) molecule labeled with the beta-emitting radionuclide lutetium-177 (^177Lu^). The drug specifically binds to FAP, which is highly expressed on cancer-associated fibroblasts in the tumor microenvironment of many epithelial cancers. Upon binding, the radioactive payload delivers localized radiation to tumor tissue while sparing most normal tissues. This approach enables both imaging and therapeutic ("theranostic") applications. The compound has demonstrated stability in biological media and promising anti-tumor efficacy in preclinical models and early clinical studies. The "FUSCC" designation indicates development or association with Fudan University Shanghai Cancer Center.
- Brand names
- 177Lu-FAPI-FUSCC
- Other names
- [177Lu]FAPI FUSCC[177Lu]Lu-FAPI-FUSCC177Lu FAPI FUSCC injection
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 177Lu-FAPI-FUSCC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-FAPI-FUSCC.